ASPH


Objective

  • To determine the effectiveness of atypical antipsychotic (olanzapine, quetiapine, risperidone) PAPs
  • To contrast their acceptance percentage, approval period and total cost savings incurred.

Methods

  • N=320 indigent patients receiving an atypical antipsychotics
  • Multi-center study (12 different sites) throughout Alameda Co., California
  • 1 year evaluation period (7/1/2000 – 6/30/2001)

Results

Antipsychotic Approval Rate Total Rxs Mean Rxs/app Total Savings
Olanzapine 65% 614 5.8 $ 157,798
Quetiapine 61% 61 2.4 $ 13,237
Risperidone 54% 176 2.8 $ 30,096

Evaluation

  • Favorable program characteristics:
    • provider eligibility determination
    • bulk medication shipment
    • long (6-9 month) program eligibility period
    • email interface
  • 65% of study patients achieved MediCaid (MediCal) eligibility at 12 months,
  • Olanzapine program resulted in the greatest success as measured by:
    • approval rate, total prescriptions,
    • mean prescriptions per application and
    • total cost savings.

Conclusions

  • None of the programs ideal for use by County system
  • Programs need to streamline application process, provide bulk meds, and have longer eligibility periods


BHCS MIA 2001: Percentage Approved Applications per Atypical Antipsychotic


BHCS MIA 2001: # Rxs/Approved Application 


BHCS MIA 2001:
Total Cost Savings per Atypical Antipsychotic